Contact Us   |   Print Page   |   Sign In   |   Join
News and Press: Member Organization News

Millendo Therapeutics begins Phase 2 trial of ATR-101

Tuesday, June 14, 2016   (0 Comments)
Posted by: Kate Oesterle
Share |

Drug to be tested on patients with rare endocrine disorder

Ann Arbor-based Millendo Therapeutics Inc. has begun Phase 2 U.S. Food and DrugAdministration trials at the University ofMichigan Health System of a drug candidate called ATR-101 on patients with classic congenital adrenal hyperplasia (CAH), a rare inherited endocrine disorder characterized by overgrowth of the adrenal glands.

The trial, which will eventually involve 15-20 patients at six or seven medical centers around the U.S., will evaluate safety, efficacy and effective dosing levels.

CAH can lead to severe virilization in females, testicular tumors in men and infertility.

ATR-101 is also being studied in a Phase 1 clinical trial in patients with adrenocortical carcinoma.

Read more.

Creating Value
by delivering business-critical resources & bottom line savings
Building Networks
by connecting Michigan's bio-industry one member at a time
Growing Talent
by creating opportunities that develop people & build organizations
Membership Software Powered by YourMembership  ::  Legal